Health ❯ Healthcare ❯ Clinical Trials ❯ Obesity

Semaglutide

Phase 3 Trials Show Greater Weight Loss With 7.2 mg Injection and 25 mg Oral Semaglutide

Regulators are assessing new dosing options following trial results showing greater weight loss with added side effects.

Half of Semaglutide Users Quit Within a Year as Higher Dose Trials Show Bigger Losses, More Side Effects